Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists.
The purpose of this paper is to provide information about cost-effectiveness analysis and the roles of clinical pharmacologists generally in providing efficient health care. The paper highlights the potential consequences of 'off-label prescribing' and 'indication creep' behaviour given slower growth (or potential cuts) in the NHS budget. This paper highlights the key roles of clinical pharmacologists in delivering an efficient health care system when resources are allocated using cost-effectiveness analyses. It describes what cost-effectiveness analysis (CEA) is and how incremental cost-effectiveness ratios (ICERs) are used to identify efficient options. After outlining the theoretical framework within which using CEA can promote the efficient allocation of the health care budget, it considers the place of disinvestment within achieving efficient resource allocation. Clinical pharmacologists are argued to be critical to providing improved population health under CEA-based resource allocation processes because of their roles in implementation and disinvestment. Given that the challenges facing the United Kingdom National Health Service (NHS) are likely to increase, this paper sets out the stark choices facing clinical pharmacologists.
Edlin
Richard
R
Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Round
Jeff
J
Hulme
Claire
C
McCabe
Christopher
C
D002017:Budgets; D003362:Cost-Benefit Analysis / Q000191:economics*; D016527:Drug Costs; D004363:Drug Utilization / Q000191:economics*; D017850:Economics, Pharmaceutical; D006801:Humans; D010595:Pharmacists / Q000191:economics; D013222:State Medicine / Q000191:economics*; D006113:United Kingdom